Want to see HK:9960 full AI Analyst Report?
9960 Stock Chart & Stats
HK$1.17
HK$0.05(4.55%)
At close: 4:00 PM EST
HK$1.17
HK$0.05(4.55%)
Day’s Range― - ―
52-Week RangeHK$0.91 - HK$1.75
Previous CloseN/A
Volume114.00K
Average Volume (3M)956.95K
Market Cap
HK$968.43M
Enterprise Value-HK$64.53
Total Cash (Recent Filing)HK$1.56B
Total Debt (Recent Filing)HK$438.12M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield10.22%
Share Statistics
EPS (TTM)-0.06
Shares Outstanding1,041,326,700
10 Day Avg. Volume603,200
30 Day Avg. Volume956,950
Financial Highlights & Ratios
PEG Ratio-6.54
Price to Book (P/B)0.37
Price to Sales (P/S)1.07
P/FCF Ratio22.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow debt-to-equity and a sizable equity base provide durable financial resilience, lowering refinancing and interest risk. This conservatism gives the company flexibility to weather demand weakness, invest in lab capacity or R&D, and support operations without relying on volatile external financing.
2025 Cash-flow TurnaroundA return to positive operating and free cash flow demonstrates the business can generate internal funding when headwinds ease. Sustainable cash generation strengthens reinvestment capacity, reduces dependency on debt/equity raises, and underpins longer-term operational stability if maintained.
Higher-margin Specialized TestingA fee-for-service model with advanced molecular/genetic tests supports superior per-test economics versus routine assays. Structural demand for specialized diagnostics and higher unit pricing can sustain gross margins and allow margin expansion if volume mix shifts toward advanced services over time.
Bears Say
Prolonged Revenue DeclineThree consecutive years of material revenue decline indicate persistent demand or market-share challenges. Sustained top-line contraction undermines operating leverage, constrains reinvestment, and makes it harder to restore profitability unless the company reverses the trend or materially improves its test mix or client access.
Continued Losses And Weak ReturnsOngoing net losses and negative ROE show the business is not generating acceptable returns on capital. Persistent unprofitability erodes shareholder equity over time and limits strategic options unless margins recover, making sustainable value creation uncertain without structural improvements.
Volatile Cash GenerationHistoric swings from deep negative to positive free cash flow signal inconsistent cash conversion. Volatility hampers planning, increases reliance on external funding in down years, and raises execution risk for capital-intensive lab upgrades or expansion unless cash generation becomes consistently positive.
Kindstar Globalgene Technology, Inc. News
9960 FAQ
What was Kindstar Globalgene Technology, Inc.’s price range in the past 12 months?
Kindstar Globalgene Technology, Inc. lowest stock price was HK$0.91 and its highest was HK$1.75 in the past 12 months.
What is Kindstar Globalgene Technology, Inc.’s market cap?
Kindstar Globalgene Technology, Inc.’s market cap is HK$968.43M.
When is Kindstar Globalgene Technology, Inc.’s upcoming earnings report date?
Kindstar Globalgene Technology, Inc.’s upcoming earnings report date is Sep 02, 2026 which is in 31 days.
How were Kindstar Globalgene Technology, Inc.’s earnings last quarter?
Kindstar Globalgene Technology, Inc. released its earnings results on Mar 30, 2026. The company reported -HK$0.025 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Kindstar Globalgene Technology, Inc. overvalued?
According to Wall Street analysts Kindstar Globalgene Technology, Inc.’s price is currently Overvalued.
Does Kindstar Globalgene Technology, Inc. pay dividends?
Kindstar Globalgene Technology, Inc. pays a Annually dividend of HK$0.095 which represents an annual dividend yield of 10.22%. See more information on Kindstar Globalgene Technology, Inc. dividends here
What is Kindstar Globalgene Technology, Inc.’s EPS estimate?
Kindstar Globalgene Technology, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Kindstar Globalgene Technology, Inc. have?
Kindstar Globalgene Technology, Inc. has 1,041,326,700 shares outstanding.
What happened to Kindstar Globalgene Technology, Inc.’s price movement after its last earnings report?
Kindstar Globalgene Technology, Inc. reported an EPS of -HK$0.025 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.633%.
Which hedge fund is a major shareholder of Kindstar Globalgene Technology, Inc.?
Currently, no hedge funds are holding shares in HK:9960
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Kindstar Globalgene Technology, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
9.75%
12-Months-Change
Fundamentals
Return on Equity
10.22%
Trailing 12-Months
Asset Growth
4.10%
Trailing 12-Months
Company Description
Kindstar Globalgene Technology, Inc.
Kindstar Global (Beijing) Technology, Inc. is a prominent provider of highly specialized diagnostic services to healthcare institutions across China. Beyond just diagnostics, the company extends its expertise to support medical research, clinical drug trials, and translational medicine initiatives for a diverse client base, including individual practitioners, research organizations, various hospital types, and pharmaceutical firms. This broad service portfolio is underpinned by its extensive, state-of-the-art laboratory infrastructure, which encompasses disciplines such as flow cytometry, cytogenetics, medical genomics, molecular biology, hematopathology, mass spectrometry, pathology, clinical immunology, and microbiology, alongside dedicated scientific research labs. Kindstar Global offers a comprehensive range of diagnostic tests covering key areas like hematology (blood), oncology (tumor), and genetic disorders. Its capabilities also extend to diseases affecting the cardiovascular and cerebrovascular systems, infectious agents, and autoimmune conditions, supporting various medical specialties including internal medicine, surgery, gynecology, pediatrics, and numerous other clinical fields. Established in 2003, the company maintains its headquarters in Wuhan, China.
Technical Analysis
Jinxin Fertility Group Ltd.
―
Town Health International Medical Group Ltd.
―
Hygeia Healthcare Holdings Co., Ltd.
―
JD Health International, Inc.
―
Concord Healthcare Group Co., Ltd. Class H
―